yzirapogyg.wordpress.com
Meelia had been a Haemonetics director since 2005 and his term was set to expirsin 2011. The company said Meeli a stepped down to spend more time and energ in his executive role atCovidien (NYSE: COV), a Bermuda-based developerf of medical devices and imaging solutions, among other healtjh care products, according to a filing with the . In a separatre regulatory filing Wednesday, the companh outlined the compensation parameters for newly hire d CEO Brian Concannon and executiv e chairmanBrad Nutter. Concannon will receive $550,000 in salary and stands to earnanothedr $412,500 in bonuses if certain operating and managementr milestones are met.
Concannon also received options tobuy 32,853 shares of Haemonetics common stock and was grantedx 2,053 shares of its restricted stock. Haemonetics HAE), based in Braintree, Mass., also outlined several change-in-control provisionw that could pay Concannon up to three times his annual pay if a companu or person acquires 35 percent of Haemoneticxscommon stock. Nutter, the company’s former CEO, will receive $300,00 0 in annual pay as both Haemonetics board’sa executive chairman. He also remains an employee ofthe company, although his role was not detailedr in Wednesday’s filing.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment